128 related articles for article (PubMed ID: 30610925)
1. CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia.
Jaiswal SR; Bhakuni P; Joy A; Kaushal S; Chakrabarti A; Chakrabarti S
Biol Blood Marrow Transplant; 2019 Apr; 25(4):673-682. PubMed ID: 30610925
[TBL] [Abstract][Full Text] [Related]
2. Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects.
Jaiswal SR; Chakraborty S; Lakhchaura R; Shashi P; Mehta A; Soni M; Chakrabarti S
Transplant Cell Ther; 2021 Feb; 27(2):144-151. PubMed ID: 33830023
[TBL] [Abstract][Full Text] [Related]
3. CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies.
Jaiswal SR; Bhakuni P; Bhagawati G; Aiyer HM; Soni M; Sharma N; Jaiswal RR; Chakrabarti A; Chakrabarti S
Bone Marrow Transplant; 2021 Jan; 56(1):185-194. PubMed ID: 32704091
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation.
Jaiswal SR; Chakrabarti S
Immunotherapy; 2019 Oct; 11(14):1221-1230. PubMed ID: 31478424
[TBL] [Abstract][Full Text] [Related]
5. CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study.
Jaiswal SR; Aiyer HM; Rawat G; Gera A; Chakrabarti S
Exp Hematol; 2019 Sep; 77():26-35.e1. PubMed ID: 31449833
[TBL] [Abstract][Full Text] [Related]
6. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions.
Jaiswal SR; Zaman S; Chakrabarti A; Sen S; Mukherjee S; Bhargava S; Ray K; O'Donnell PV; Chakrabarti S
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1867-1873. PubMed ID: 27470289
[TBL] [Abstract][Full Text] [Related]
7. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
9. Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.
Jaiswal SR; Bhakuni P; Bhagwati G; Aiyar HM; Chakrabarti A; Chakrabarti S
Transplantation; 2020 Jan; 104(1):e23-e30. PubMed ID: 31478993
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
11. Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.
Gilman AL; Leung W; Cowan MJ; Cannon M; Epstein S; Barnhart C; Shah K; Hyland M; Fukes T; Ivanova A
Am J Hematol; 2018 Feb; 93(2):169-178. PubMed ID: 29047161
[TBL] [Abstract][Full Text] [Related]
12. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
13. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study.
Huang XJ; Wang Y; Liu DH; Xu LP; Chen H; Chen YH; Han W; Shi HX; Liu KY
J Clin Immunol; 2008 Jul; 28(4):390-7. PubMed ID: 18347959
[TBL] [Abstract][Full Text] [Related]
14. Early Cytomegalovirus Reactivation and Expansion of CD56
Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
[TBL] [Abstract][Full Text] [Related]
15. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant.
Yan C; Xu L; Liu D; Chen H; Wang Y; Liu K; Huang X
Chin Med J (Engl); 2014; 127(20):3602-9. PubMed ID: 25316237
[TBL] [Abstract][Full Text] [Related]
17. Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Kang YL; Lee JH; Lee JH; Kim DY; Lee JL; Park HS; Choi EJ; Lee YS; Kang YA; Jeon M; Seol M; Baek S; Yun SC; Kim HJ; Lee KH
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2065-2076. PubMed ID: 27530969
[TBL] [Abstract][Full Text] [Related]
18. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.
Brehm C; Huenecke S; Quaiser A; Esser R; Bremm M; Kloess S; Soerensen J; Kreyenberg H; Seidl C; Becker PS; Mühl H; Klingebiel T; Bader P; Passweg JR; Schwabe D; Koehl U
PLoS One; 2011; 6(11):e27351. PubMed ID: 22096557
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
20. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
